140 related articles for article (PubMed ID: 23037730)
1. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid Leukemia - clinical practice according to the JSH guideline for hematological malignancies].
Yahagi Y
Gan To Kagaku Ryoho; 2014 May; 41(5):567-71. PubMed ID: 24956628
[No Abstract] [Full Text] [Related]
3. [Chronic myeloid leukemia: up-to-date management].
Nakayama K; Inokuchi K
Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
[No Abstract] [Full Text] [Related]
4. [Standard therapy for chronic myelogenous leukemia].
Kimura S
Rinsho Ketsueki; 2012 Oct; 53(10):1571-80. PubMed ID: 23037729
[No Abstract] [Full Text] [Related]
5. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Saito M; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Saga A; Musashi M; Kato T; Meguro T; Tanino M
Rinsho Ketsueki; 2014 Jan; 55(1):130-2. PubMed ID: 24492046
[TBL] [Abstract][Full Text] [Related]
6. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
7. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
8. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
[TBL] [Abstract][Full Text] [Related]
9. [Management of chronic myeloid leukemia].
Kubuki Y
Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
[No Abstract] [Full Text] [Related]
10. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
12. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Anzalone CL; Cohen PR; Kurzrock R; Cortes JE
Dermatol Online J; 2014 Jan; 20(1):21242. PubMed ID: 24456946
[TBL] [Abstract][Full Text] [Related]
13. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
14. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
Yadav U; Solanki SL; Yadav R
J Cancer Res Ther; 2013; 9(3):484-6. PubMed ID: 24125987
[TBL] [Abstract][Full Text] [Related]
16. [Glivec induced autoimmune hepatitis].
Charier F; Chagneau-Derrode C; Levillain P; Guilhot F; Silvain C
Gastroenterol Clin Biol; 2009; 33(10-11):982-4. PubMed ID: 19765927
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Xu LP; Huang XJ
Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
[No Abstract] [Full Text] [Related]
19. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
20. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Breccia M; Alimena G
Leuk Res; 2013 Jun; 37(6):713-20. PubMed ID: 23473918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
